(2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide is a complex heterocyclic compound featuring a pyrrolidine core linked to a substituted thiazole and a trifluoromethyl-substituted pyridine moiety. This specific stereochemistry and substitution pattern are characteristic of advanced pharmaceutical intermediates. This compound is a key intermediate in the synthesis of Sotorasib (AMG 510), a first-in-class, highly selective covalent inhibitor of the KRAS G12C mutant protein. KRAS G12C mutations are prevalent in several cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic adenocarcinoma. As a critical synthetic building block, this intermediate is used in the final steps of constructing the active pharmaceutical ingredient (API) that directly targets and irreversibly inhibits the oncogenic KRAS G12C protein. Its role is pivotal in the commercial production of Sotorasib, a breakthrough targeted therapy approved for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC. The synthesis and quality control of this intermediate are strictly regulated to ensure the purity and efficacy of the final drug product.